BioSante Pharmaceuticals to Participate on Panel at BIO CEO & Investor Conference

BioSante Pharmaceuticals, Inc. (AMEX:BPA) today
announced that Stephen M. Simes, president and chief executive
officer, will participate in a panel discussion at the 8th annual BIO
CEO & Investor Conference. Mr. Simes will serve as a panelist at the
"What is New in Sexual/Gender Health?" Reproductive Focus Session, to
be held Tuesday, February 14 at 4:00 p.m. ET at the Waldorf-Astoria
Hotel in New York City.
   The panel will discuss new research developments in reproductive
health for men and women, and how pharmaceutical and biotech companies
approach this market. To listen to the audio webcast, visit
http://ceo.bio.org/opencms/ceo/2006/index.jsp. For more information
about the BIO CEO & Investor Conference, visit www.ceo.bio.org.

   About BioSante Pharmaceuticals, Inc.

   BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver bioidentical
estradiol and testosterone. BioSante's lead products include
Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women
with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone
gel) for the treatment of female sexual dysfunction (FSD). The current
market in the U.S. for estrogen and testosterone products is
approximately $2.5 billion. The transdermal gel formulations used in
the women's gel products are licensed by BioSante from Antares Pharma
Inc. BioSante also is developing its calcium phosphate nanotechnology
(CaP) for novel vaccines, including biodefense vaccines for toxins
such as anthrax and ricin, and drug delivery systems. Additional
information is available online at: www.biosantepharma.com.